Navigation Links
Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
Date:11/18/2010

ood tolerability of AEZS-108 was also reflected by a low rate of severe possibly drug-related non-hematological adverse events and which included single cases (2.4%) each of nausea, diarrhea, fatigue, general health deterioration (Grade 4), creatinine elevation, and blood potassium decrease. No cardiac toxicity was reported. Conclusion

  • AEZS-108 at a dosage of 267 mg/m2 every 3 weeks was active and well tolerated in patients with endometrial cancer.
  • Hematological toxicity was rapidly reversible, and non-hematological toxicities were usually not severe, causing few deviations from scheduled treatment.
  • The objective response rate of 31% compares well with those of single agent platinum or taxane treatment; responders included patients pre-treated with platinum/taxane combination.
  • In addition, the rate of stable disease was 44%, resulting in a Clinical Benefit Rate of 74%.
  • The overall survival after single agent AEZS-108 is similar to that reported for modern triple combination chemotherapy, but was achieved with lower toxicity. 
  • The abstract is available at: cr="true" href="http://www.aezsinc.com/temp/poster378.html">http://www.aezsinc.com/temp/poster378.html About Endometrial Cancer This year, the American Cancer Society estimates that more than 43,000 cases of endometrial cancer - tumors in the lining of the uterus and the glands of the endometrium - will be diagnosed in the United States. Symptoms can include unexplained vaginal bleeding, painful urination, painful intercourse and soreness in the pelvic area. There is no routine test to identify endometrial cancer. Treatment options include surgery, radiation therapy, hormone therapy and chemotherapy; however, there are new treatments in development that work by targeting and destroying cancerous cells. About AEZS-108 AEZS-108 represents a new targeting concept in
    '/>"/>

    SOURCE AETERNA ZENTARIS INC.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
    2. Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
    3. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
    4. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
    5. Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
    6. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
    7. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
    8. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
    9. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
    10. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
    11. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... observed tiny quantum vortices in cold droplets of liquid ... that the exotic vortices arrange themselves as densely ... time that the quantum vortices, which have already been ... superfluid helium, have been detected in nanodroplets. "The experiment ... the University of Southern California, one of the experiment,s ...
    (Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
    (Date:8/21/2014)... Aug. 21, 2014 Telomere Biosciences, LLC ... Nutraceutical "TELO-20 for Dogs" with Telomerase Activation ... in the world for dogs. Telomeres are the ... in the body. A wealth of ground-breaking research ... Telomere Science and Aging, including Nobel laureates, has ...
    (Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
    Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
    ... Synthetic Biologics, Inc.  (NYSE Amex: ... and innovative disease-modifying medicines for serious illnesses, announced ... a Phase II clinical trial evaluating the efficacy ... of estriol (Trimesta™) for the treatment of relapsing-remitting ...
    ... JERICHO, N.Y., March 13, 2012   Health Care ... Via Christi Health System of Wichita, Kansas has ... rate just two months after selecting and implementing ... COI disclosure process. (Logo: http://photos.prnewswire.com/prnh/20061010/NYTU194LOGO ...
    ...  Good Shepherd Rehabilitation Network ( www.GoodShepherdRehab.org ), an ... and cognitive disabilities, today received the third Ekso ... called eLEGS) is a wearable, bionic robot by ... with lower-extremity paralysis or weakness to stand and ...
    Cached Biology Technology:Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 2Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 3Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 4Conflict of Interest Management System Selected by Via Christi Health 2Conflict of Interest Management System Selected by Via Christi Health 3Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton 2Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton 3
    (Date:8/21/2014)... Carolina State University have developed a novel and versatile ... applications for creating new materials as well as for ... technique allows us to model much larger and more ... quickly," says Nan Li, lead author of a paper ... State,s Department of Materials Science and Engineering. "This is ...
    (Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
    (Date:8/20/2014)... Calif., August 19, 2014 -- Bay Area Lyme Foundation, ... and simple to cure, applauds new research published in ... Ticks and Tick-borne Diseases . The findings ... California are active throughout the year, making the threat ... researchers at California Department of Public Health (CDPH) Vector-borne ...
    Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
    ... Toronto chemists have made a major contribution to the emerging ... photosynthesis in marine algae. "There,s been a lot of ... practices," says chemistry professor Greg Scholes, lead author of a ... "Our latest experiments show that normally functioning biological systems have ...
    ... mountains are thinning is not disputed. However, few researchers ... Lawrence Berkeley National Laboratory scientist Surabi Menon set out ... culpritgreenhouse gases, such as carbon dioxidefrom other particles in ... and her collaborators found that airborne black carbon aerosols, ...
    ... 3, 2010 For Immediate Release A team of ... that act on novel binding sites for an enzyme used ... AIDS. The discovery lays the foundation for the development of ... treat drug-resistant strains of the disease, and slow the evolution ...
    Cached Biology News:Scientists find quantum mechanics at work in photosynthesis 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 2Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 4Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 5
    ... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
    Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
    CCNI Antibody...
    ...
    Biology Products: